Tagged with R

Pharma Legal Handbook Key information on patents and trademarks in Greek pharma. Prepared in association with Calavros Law Firm, a leading global law firm, this is an extract from The Pharma Legal Handbook: Greece, available to purchase here for USD 99.   1. What are the basic requirements to obtain patent and trademark protection? Patents Currently,…

Pharma Legal Handbook Regulatory reforms in Greece – a comprehensive legal overview. Prepared in association with Calavros Law Firm, a leading global law firm, this is an extract from The Pharma Legal Handbook: Greece, available to purchase here for USD 99.   1. Are there proposals for reform or significant change to the healthcare system? A.…

Pharma Legal Handbook All legal aspects surrounding cannabinoid drugs, medicinal cannabis & opioid drugs in Greece. Prepared in association with Calavros Law Firm, a leading global law firm, this is an extract from The Pharma Legal Handbook: Greece, available to purchase here for USD 99.   Cannabinoid Drugs 1. Are Cannabinoid Drugs authorized in your country?…

Europe 125 medicines for rare diseases were approved by the EMA between 2004 and 2014, of which 71 were granted orphan drug status. This chart shows the availability of 112 of these drugs across European countries. The largest number of medicines for rare diseases were in continuous use in Germany and…

Korea Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the many countries known for their misuse of antibiotics but now it looks as though the country is ready to join…

Turkey Uğur Bingöl, general manager of Ibrahim Etem Menarini, speaks of his company’s rapid growth and new product lines. He also describes his take on the Turkish pharmaceutical market and outlines his strategic priorities to continue growing Ibrahim Etem Menarini’s presence in Turkey.   We are committed to the localization movement…

IFPMA Last week, the IFPMA released their new Code of Practice with the aim of encouraging complete integrity and ethical responsibility within the pharmaceutical industry. We do not want anything to even potentially suggest that we are trying to get between the healthcare professional and the patient at the time of…

Opinion Axel Schumacher, co-founder and chief scientific officer of Shivom, a data-driven next generation precision-medicine company in the blockchain space, calls for Pharma to leverage big-data on a global level to ensure all patients have a therapy option.    The key to success for pharma players is to sponsor the accumulation of…

Korea Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market, emphasizing the importance of volume over price. He also concludes that Korea should focus on establishing itself as a leader…

Korea The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced technologies to drive the nation’s economic growth as well as better care for patients at home and abroad.   For…

Spain Luis Serrano, president of the Centre for Genomic Regulation (CRG) in Spain, gives an update on the Centre’s recent history and outlines the need for greater understanding of science and research within the Spanish political class.   When we enter discussions with the different political parties, I feel things are…

France Jean-Luc Belingard, president of FEFIS (Fédération Française des Industries de Santé – French Federation of the Health Industry), explains his role following up on the implementation of the CSIS (Conseil stratégique des industries de santé – Strategic council of the healthcare industry) and speaks out about the competitiveness of the…